Review: Dipeptidyl peptidase-4 inhibitors do not increase overall adverse events in type 2 diabetes

被引：2
作者：
Chatterjee, Saurav [1 ,2 ]
Chatterjee, Sanjay [3 ]
机构：
[1] Brown Univ, Providence, RI 02912 USA
[2] Providence VAMC, Providence, RI USA
[3] Apollo Gleneagles Hosp, Kolkata, W Bengal, India
来源：
ANNALS OF INTERNAL MEDICINE | 2013年 / 158卷 / 08期
关键词：
METAANALYSIS;
D O I：
10.7326/0003-4819-158-8-201304160-02008
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Dipeptidyl peptidase-4 inhibitors reduce the incidence of first cardiovascular events in Japanese diabetic patients
    Soejima, Hirofumi
    Ogawa, Hisao
    Morimoto, Takeshi
    Okada, Sadanori
    Matsumoto, Chisa
    Nakayama, Masafumi
    Masuda, Izuru
    Jinnouchi, Hideaki
    Waki, Masako
    Saito, Yoshihiko
    JPAD Trial Investigators
    HEART AND VESSELS, 2023, 38 (11) : 1371 - 1379
  • [22] Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes A system review and meta-analysis
    Wang, Ben
    Sun, Yan
    Sang, Yiquan
    Liu, Xuekui
    Liang, Jun
    MEDICINE, 2018, 97 (46)
  • [23] Association of Sodium-Glucose Cotransporter-2 Inhibitors vs Dipeptidyl Peptidase-4 Inhibitors With Pneumonia, COVID-19, and Other Adverse Respiratory Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
    Wang, Mengna
    Li, Ming
    Wang, Libin
    Wang, Fang
    Cao, Xulin
    Li, Shengyou
    Zheng, Zhichang
    CANADIAN JOURNAL OF DIABETES, 2024, 48 (06) : 364 - 372.e1
  • [24] Dipeptidyl peptidase-4 inhibitors and risk of arthralgia: A systematic review and meta-analysis
    Men, P.
    He, N.
    Song, C.
    Zhai, S.
    DIABETES & METABOLISM, 2017, 43 (06) : 493 - 500
  • [25] Treatment progression in sulfonylurea and dipeptidyl peptidase-4 inhibitor cohorts of type 2 diabetes patients on metformin
    Peng, Xiaomei
    Jiang, Dingfeng
    Liu, Dongju
    Varnado, Oralee J.
    Bae, Jay P.
    PATIENT PREFERENCE AND ADHERENCE, 2016, 10 : 1539 - 1546
  • [26] Associations of dipeptidyl peptidase-4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus
    Sato, Akihiko
    Yoshihisa, Akiomi
    Kanno, Yuki
    Takiguchi, Mai
    Miura, Shunsuke
    Shimizu, Takeshi
    Nakamura, Yuichi
    Yamauchi, Hiroyuki
    Owada, Takashi
    Sato, Takamasa
    Suzuki, Satoshi
    Oikawa, Masayoshi
    Yamaki, Takayoshi
    Sugimoto, Koichi
    Kunii, Hiroyuki
    Nakazato, Kazuhiko
    Suzuki, Hitoshi
    Saitoh, Shu-ichi
    Takeishi, Yasuchika
    ESC HEART FAILURE, 2016, 3 (02): : 77 - 85
  • [27] Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trials
    Chai, Shangyu
    Zhang, Ruya
    Zhang, Ye
    Carr, Richard David
    Zheng, Yiman
    Rajpathak, Swapnil
    Yu, Miao
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [28] Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes in Taiwan A Population-Based Cohort Study
    Lai, Yun-Ju
    Hu, Hsiao-Yun
    Chen, Hsin-Hua
    Chou, Pesus
    MEDICINE, 2015, 94 (43)
  • [29] Systematic review and meta-analysis: dipeptidyl peptidase-4 inhibitors and rheumatoid arthritis risk
    Wang, Miao
    Li, Muqin
    Xie, Ying
    ENDOCRINE JOURNAL, 2021, 68 (06) : 729 - 738
  • [30] Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials
    Mannucci, Edoardo
    Nreu, Besmir
    Montereggi, Chiara
    Ragghianti, Benedetta
    Gallo, Marco
    Giaccari, Andrea
    Monami, Matteo
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2021, 31 (10) : 2745 - 2755
12345